Is cabozantinib useful after capmatinib resistance?

Capmatinib (Capmatinib), as a lung cancer drug targeting MET mutations, has brought hope to many patients. However, the issue of drug resistance is always a challenge in cancer treatment, and capmatinib is no exception. When resistance to capmatinib occurs, patients and doctors often look for other effective treatment options. Cabozantinib (Cabozantinib), as a multikinase inhibitor, has become an option that has attracted much attention.

Capmatinib has shown significant efficacy in the treatment of patients with MET mutated non-small cell lung cancer (NSCLC). However, the problem of drug resistance remains unavoidable. It has been found in clinical trials and practical applications that some patients will develop drug resistance after using capmatinib for a period of time, which may be due to various mutations and adaptation mechanisms of tumor cells. This resistance causes cells that were originally sensitive to capmatinib to become no longer responsive to the treatment.

Cabozantinib is a multi-target small molecule tyrosine kinase inhibitor with broad anti-tumor activity. It achieves anti-tumor effects by inhibiting multiple kinases related to tumor growth and angiogenesis, such as MET, VEGFR, RET, etc. This multi-target inhibitory feature makes it possible for cabozantinib to overcome resistance generated by single-target drugs (such as capmatinib).

Cabozantinib has shown potential therapeutic effect for patients who are resistant to capmatinib. Some studies have shown that cabozantinib can overcome cabozantinib resistance caused by specific gene mutations or amplifications. For example, cabozantinib may still be effective in patients with genomic mutations in the kinase domain of MET. In addition, cabozantinib can be used in combination with other tyrosine kinase inhibitors to reduce the occurrence of primary resistance.

Existing research results show certain efficacy. In some case reports and small studies, cabozantinib has successfully controlled tumors in some patients who were resistant to cabozantinib. However, it is important to note that each patient's specific situation is different, so the efficacy of cabozantinib will also vary from individual to individual.